About
Clinical Research Malaysia
Clinical Research Malaysia (CRM) is a Global Trusted Research Management Organisation
established by the Ministry of Health Malaysia in 2012. The organisation is guided by the principlesof Humanity, Stability and Sustainability in providing global clinical trial solutions and enablinga thriving clinical research ecosystem in the country. At its very core, CRM aims to bring clinicalresearch that addresses the unmet needs of patients and transforms health outcomes in Malaysia.
CRM delivers sponsored clinical trials with Speed, Reliability and Quality through operational
excellence and working with stakeholders by providing end-to-end clinical research support
services. Certified with both ISO 9001:2015 (Quality Management System) and ISO 37001:2016(Anti-Bribery Management System), and being aligned to international regulations, our core values
and code of conduct are ingrained throughout CRM. The strength of this organisation lies in thepeople of CRM as we strive in our vision to make Malaysia the preferred clinical research hub in Asia.

From The
CEO's Desk
Warmest welcome to CRM Bulletin 28!
As the midpoint of 2024 is passing by, it’s remarkable to reflect
on the significant achievements and impactful events that haveshaped these past few months. The pace of progress has beenswift, but the results speak volumes.
In this edition, we’re excited to highlight of our recent milestones,
introduce to the dedicated team driving our mission, and review
our recruitment successes for the year. We proudly mark the returnof CRM Trial Connect, our annual international conference, which
included two insightful workshops held in collaboration with
the European Organization for Research & Treatment of Cancer(EORTC), the National Cancer Center Japan (NCC), and the NPRA.
This event was a key opportunity for us to strengthen existing
partnerships and forge new ones.
We are particularly thrilled to announce that Malaysia ranks among
the Top 30 countries globally and 1st in Southeast Asia for country
readiness in global clinical trials according to IQVIA report on“Rethinking Clinical Trial Country Prioritisation.” This milestonereflects our growing excellence and readiness in clinical research.
We’re also honoured to have received the prestigious UK-Malaysia
Partnership of the Year Award, recognising our commitment toclinical trials and governance.
This bulletin also features the inspiring journey of one of ourprincipal investigators and a deep dive into one of our sites. Here’s
to a continued journey of innovation and success in the rest of2024!
Our commitment to Humanity, Stability, and Sustainability
remains at the core of our operations. We remain committed todelivering clinical trials with Speed, Reliability, and Quality, driven
by our operational excellence and robust partnerships
Thank you to our partners, stakeholders, and the entire CRM
team for your unwavering support. Together, we will continue toadvance healthcare and research in Malaysia and beyond.
Dr. Akhmal Yusof
CEO, Clinical Research Malaysia

www.clinicalresearch.my

TABLE OFCONTENTSHIGHLIGHTS

3

SPOTLIGHT FEATURE• CRM Trial Connect 2024
• Sponsored Research Awards
2024• CEO Award 2023
• CRM Won the Business
Excellence Award 2024 for
UK-Malaysia Partnership of
the Year• Malaysia Ranks 1st inSoutheast Asia for Country
Readiness in Global Clinical
Trials• Malaysia Chosen byInternational Organisations
as Clinical Trial Hub in the
Region• Partnership Forged with
Singapore Research
Organisations

6

RESEARCH PERSONALITYDr Syazatul Syakirin

12

RISING STARS IN
NEPHROLOGY14

INFOGRAPHIC

16

FEATURED SITE
19
• Institut Perubatan Respiratori(IPR)
MEET OUR TEAM
• Alvin Bundoi• Cheng Shu Hui

22

PUBLICATION

24

CRM IN PHOTOS

26

1

2

HIGHLIGHTS
Mastering Project Management
for Clinical Trials
8 May 2024 – A large group of experienced SCs attended the‘Project Management in Clinical Trials’ training led by Ms.
Adeline Yeoh from Syneos Health. The session covered how
project management concepts and tools can be effectively
applied to coordinate clinical trial activities at the site.

PMCC’s Mission of Excellence: A
Collaborative Partnership withCRM
6 May 2024 – CRM's collaborative partnership with the
Princess Margaret Cancer Centre (PMCC) led to PMCC's
Mission of Excellence to Malaysia. The team visited FIH site,
Sarawak General Hospital and connected with the team there
in the early part of their visit.

IC3D 2024 Conference
13 - 14 May 2024 – CRM attended the International Conference
on Drug Discovery and Development (IC3D) 2024, alongwith Dr. Voon Pei Jye as one of the speakers presented
on enhancing outcomes with early phase oncology trials
and valuable insights into innovative methodologies andstrategies for advancing cancer treatment and improving
patient outcomes.

Best Practices in Phase I Studies:
Insights from Princess Margaret
Cancer Centre
8 May 2024 – Ms. Gagan Sran, Ms. Lindsay Carlsson, and Ms.
Carey Yang from Princess Margaret Cancer Centre (PMCC)
led an insightful session with CRM Study Coordinators.
They shared best practices for managing Phase I studies
through case studies and group discussions, highlighting
the importance of proactive planning and effective
communication within the study team.

www.clinicalresearch.my

CRM at DIA China 2024
20 May 2024 – CRM and NPRA marked their presence at the
recent DIA China 2024, sharing Malaysia's value proposition
for clinical trials and the regulatory landscape of the country.

3

HIGHLIGHTS

3rd I Am Aware Roadshow of 2024
21 May 2024 – In honor of Clinical Trials Awareness Month,
CRM held its third I Am Aware Roadshow of 2024 at Miri
Hospital. The event aimed to educate the public about thebenefits of participating in clinical trials.

Patient Recruitment & Retention
Workshop 2024
29 May 2024 – CRM has successfully conducted the 2nd seriesof its Patient Recruitment & Retention workshop for 2024,
attended by 36 internal and external stakeholders. The
workshop offered valuable strategies and insights to enhancepatient engagement and improve recruitment outcomes.

Forging New Opportunities with
Novartis
29 May 2024 – Datuk Seri Dr. Dzulkefly bin Ahmad, theMinister of Health Malaysia, Datuk Dr. Muhammad Radzi
Bin Hassan, DG of Health and CRM CEO met with Dr. Lutz
Hegemann, President of Global Health & Sustainability at
Novartis, and his team from Basel. The Novartis team praised
Malaysia's excellent clinical trial delivery and expressed theircommitment to investing in new opportunities. They also
look forward to Malaysia’s role as ASEAN Chair in 2025 andits leadership in regional health initiatives, including clinicalresearch.

Virtual Protocol Compliance
Workshop 2024
29 May 2024 – CRM successfully conducted its Virtual Protocol
Compliance Workshop 2024. CRM extend our thanks to the
speakers for their invaluable insights, which will greatly
benefit attendees in their clinical tasks.

4Strengthening Global Clinical
Trial Partnerships in Basel
31 May 2024 - It was a series of productive meetings in Basel,
where the Minister of Health Malaysia and CRM CEO engaged
with several biopharmaceutical organizations, including
Novartis, Roche, BeiGene, and Swissrocket. The focus was on
positioning Malaysia as a key site for multi-regional clinical
trials, leveraging its mature ecosystem and excellence in trial
delivery. The discussions strengthened both old and newconnections, setting the stage for Malaysia to enhance its
global footprint in clinical trials.

HIGHLIGHTS
Kuala Lumpur Hospital ResearchDay
6 June 2024 - CRM participated in the 7th HKL Research Day
at Kuala Lumpur Hospital (HKL) with CRM CEO Dr. Akhmal
Yusof. The event highlighted the growth, challenges, andfuture direction of clinical research in Malaysia. A sincere
gratitude to Dr. Syazatul Syakirin Sirol Aflah from the Instituteof Respiratory Medicine for sharing her insights during the
CRM session talk.

1st Batch of CRM Centre of
Excellence Graduates
21 June 2024 - CRM Centre of Excellence concluded its 1st batchof the Foundation Program for Study Coordinators, following
12 weeks of theoretical training and site attachment. Kudos
to the trainees for completing the program and embarking on
their journey in clinical trials. CRM wished them all the best!

Malaysia Tops Southeast Asia in
Industry-Sponsored Studies
11 June 2024 - A landmark day as Malaysia leads Southeast
Asia in industry-sponsored studies for 2023-2024 (to date)!
Truly grateful for the dedicated efforts of CRM’s clinicalresearch team across public hospitals, university hospitals,
and private centers. Kudos to everyone who has supported
and enabled this ecosystem, including our regulators, EC
members, industry partners, sponsors, and CROs. Great work
truly yields fantastic results!

4th I Am Aware Roadshow of 2024
25 - 26 June 2024 – CRM successfully conducted its 4th I Am
Aware Roadshow of 2024 at Sultan Abdul Halim Hospital,
in conjunction with World Blood Donor Day. The event
highlighted the benefits of participating in clinical trials,
aiming to raise public awareness about their importance.

DIA 2024 Global Annual Meetingin San Diego

Nurturing New Talents (NNT) in
Sponsored Research 2024

18 June 2024 - CRM’s team including the Head of Clinical
Operations, and the Evaluation and Safety of Investigational
Product Section, NPRA, attended DIA2024 in San Diego. The
conference explored topics such as the future of regenerative
therapies and the role of public-private partnerships inadvancing healthcare.

26 June 2024 – CRM successfully organised NNT in SponsoredResearch at Sultan Abdul Halim Hospital. Thanks to the
speakers, Dr. Arvindran Alaga (Head of Respiratory Medicine
Department, Hospital Sultanah Bahiyah) and Dr. Balraj Sethi(Country Medical Affairs Head, Novartis) for their valuable
insights.

www.clinicalresearch.my5

HIGHLIGHTS

Advancing Clinical Research inSoutheast Asia
2 July 2024 – CRM attended a 2-day policy workshop
organized by the Academy of Medical Sciences (UK) and theAcademy of Sciences of Malaysia, focusing on advancing
diagnostics and therapeutics in Southeast Asia. CRM sharedinsights on Malaysia's clinical trial capacity building, andDr. Voon Pei Jye discussed the nation's early phase clinicalresearch development.

DIA Singapore Annual Meeting
16 - 17 July 2024 – CRM participated in the DIA Singapore
Annual Meeting 2024, joining regulators, patient
representatives, and industry leaders to foster collaborationin clinical research and regulation. The event offered valuable
insights into drug development and innovation, highlighting
the crucial role of patients, and provided impactful learningand networking opportunities.

Good Clinical Practice (GCP)
Refresher Workshop
CRM at 18th ASEAN SOMHD:
Advancing Clinical Trials
2 July 2024 – CRM represented Malaysia at the 18th ASEAN
Senior Officials' Meeting on Health Development (SOMHD),
presenting a new initiative to advance the region's prosperity
through industry-sponsored clinical trials.

6

17 July 2024 - CRM successfully conducted its 2nd series of
GCP Refresher Workshop of 2024 at Shah Alam Hospital.
The workshop aimed to enhance the knowledge and skillsof attendees in Good Clinical Practice. Special thanks to Ms.
Yoong Kai Shen for her time as the speaker. We hope theworkshop provides valuable benefits to all participants!

CRM x NCSM collaboration

Singapore Clinical ResearchInstitute (SCRI) Trials Symposium
2024

15 & 29 July 2024 – CRM and the National Cancer Society
Malaysia successfully conducted an insightful live session
on Facebook and YouTube. It was an honour to hear fromDr. Mastura, Consultant Clinical Oncologist & Radiotherapist,
Dr. Eznal, Clinical Oncologist and Mr. Safri, a clinical trial
participant, who shared their valuable stories.

30 & 31 July 2024 - CRM attended SCRI Clinical Trials
Symposium 2024, reconnecting with familiar faces andforging new relationships. CRM CEO, Dr Akhmal Yusof was
one of the speakers & panelist, sharing insights on the latest
updates in Malaysian clinical trials during the 'Trends inClinical Trials' session.

SPOTLIGHT FEATURE
CRM Trial Connect 2024

Kuala Lumpur, 9 May 2024 - Clinical Research Malaysia (CRM) successfully held its third annual conference, CRM Trial Connect 2024.
This event was preceded by two key workshops: "Biostatistics in Oncology Research" and the Regulatory Workshop. These workshops
were conducted in collaboration with the European Organization for Research & Treatment of Cancer (EORTC), the National Cancer
Center Japan (NCC), and the NPRA.
This year’s conference was held in collaboration with the European Organization for Research & Treatment of Cancer (EORTC) andthe National Cancer Center Japan. This 2-day event aimed to spotlight Malaysia’s achievements in sponsored clinical research andfoster collaborations between local and international stakeholders. Nearly 1,000 attendees from over 130 organisations, including thebiopharmaceutical and medical device industries, contract research organisations, academic institutions, and the healthcare sector,
participated in the event.
The conference was officiated by the Minister of Health, YB Datuk Seri Dr Haji Dzulkefly Ahmad, on behalf of the Malaysian Prime
Minister, at the Nexus Connexion Conference & Event Centre in Kuala Lumpur. Emphasising Malaysia's standing as one of the top
countries for sponsored clinical research in South-East Asia, the Minister of Health expressed his aspirations to attract a higher market
share of global sponsored trials to the region, highlighting the nation's supportive research landscape and diverse population.
Throughout the event, various engaging forums took place. Esteemed speakers from the public, university, and private sectors shared
their insights into the emerging industry of clinical trials in Malaysia. A patient engagement forum provided a platform for clinical trial
participants to share their journeys, while a discussion on accelerating clinical trial market growth in ASEAN was moderated by Khairy
Jamaluddin, featuring contributions panellists from ASEAN countries.
National-level discussions covered topics such as translating clinical practice into research, a Malaysian study on drug-coated balloons,and innovative approaches to trial emulation and data-linkage for vaccine effectiveness in Malaysia. One of the conference highlights
was the global network of excellence session, chaired by Dr Kenichi Nakamura from the National Cancer Center Japan (NCC). Thissession featured speakers from the NCC, ATLAS, and EORTC, who shared overviews and experiences of international clinical trials.
Additional sessions also covered regulatory and ethics tracks, early-phase clinical trial excellence, clinical research support services,and clinical trial innovation.
The conference concluded on a high note, with CRM praised for orchestrating yet another successful international event. The closing
keynote address by Datuk Dr Muhammad Radzi Abu Hassan, the Director General of Health Malaysia, summarised the key takeaways
from the two-day event, leaving attendees inspired and excited for the future of clinical research in Malaysia.

www.clinicalresearch.my7

SPOTLIGHT FEATURE

Sponsored Research Awards 2024
Kuala Lumpur, 9 May 2024 - The CRM Trial Connect Conference 2024 also acknowledged clinical research stakeholders, in conjunction
with the International Clinical Trials Day celebration. During the event, Datuk Seri Dr Haji Dzulkefly Ahmad presented the CRM ClinicalResearch Leadership Award to Datuk Amar Prof Dr Sim Kui Hian, the Deputy Premier and Minister for Public Health, Housing and Local
Government of Sarawak for his exemplary role as a pioneer in the development of clinical research in Sarawak and Malaysia. The CRM
Sponsored Research Awards were also presented during the conference to the top investigator, trial sites and industry members, forhaving achieved significant accomplishments in 2023.

8

SPOTLIGHT FEATURE

CRM CEO Awards 2023
CRM is committed to recognising and rewarding its employees who exemplify the principles of humanity, stability, and sustainability
through the Chief Executive Officer (CEO) Awards program. This annual program celebrates employees who have demonstrated
exceptional dedication and contribution to the company's mission and values.
Congratulations to all our 2023 CEO Award recipients! Your commitment to excellence and embodying CRM's core principles has not
only strengthened our team but also contributed significantly to our continued growth and success.
Individual Category
FTE Project - Ease of Workload Assesment

Alvin Bundoi
First in Human Super Rookies / Site - Sarawak General Hospital

Erfan Salbi, Fong Yian Ching, Irene Bragai Segaran & Lim Li Fang
Team Category
Global Fee - Ver! / Site - Tengku Ampuan Afzan Hospital

Adibah Hamiza, Fatma Diyana, 'Izzah Atira, Nur Liyana, Murniyati, Noor Sami'ah, Nor Naimah, Nur Ezzati
Fatin, Nur Faqihah, Suriani Yaacob, Syafiqah Hanani & Zati Nabilahwww.clinicalresearch.my9

SPOTLIGHT FEATURE
CRM Won the Business Excellence Award 2024 for UK-Malaysia
Partnership of the Year!
Kuala Lumpur, 23 May 2024 - AstraZeneca and Clinical Research Malaysia won the prestigious UKMalaysia Partnership of the Year Award, recognizing their collaboration in clinical trials, governancemeetings, and site visits. This prestigious award ceremony was hosted by the British Malaysian
Chamber of Commerce (BMCC) and representing CRM in accepting the award was Ms Zaleha Yusof,
CRM’s Head of Human Resources.
This award is a testament to the fruitful working partnership between CRM & AstraZeneca, which
saw a significant increase in clinical trials in 2023 as well as the expansion of its clinical researchteam in Malaysia. A heartfelt gratitude to CRM team for the hard work & contribution, which havebeen instrumental in achieving this successful partnership.
Assessed by a panel comprising 8 representatives from the University of Nottingham Malaysia,
6 representatives from the University of Nottingham UK, spanning China and Malaysia, and 5
representatives from the British Council, this award underscores the significant synergies fosteredthrough collaborative joint ventures.

Malaysia Ranks 1st In Southeast Asia For Country Readiness In
Global Clinical Trials
Kuala Lumpur, 26 July 2024 - Malaysia is among the Top 30 in the world and leading in Southeast
Asia in terms of country readiness for global clinical trials, according to the IQVIA report on"Rethinking Clinical Trial Country Prioritisation."
The report, which was published in July 2024, had mapped global clinical trial opportunities basedon 17 key metrics, including healthcare accessibility, clinical trial efficiency, regulatory capabilities,
and investment opportunities. Malaysia is recognised among the Top 25 countries for three outof the four clinical trial types indicated, with Indonesia as the only other Southeast Asian country
listed under one of the trial categories.
The report highlights Malaysia’s strong performance in patient availability and operational
readiness, positioning it optimally for global clinical trials. Since 2023, Malaysia has led the regionin trials, particularly in oncology, infectious diseases, and cardiology. With over 2,450 clinical trials
conducted since 2012, the industry has contributed RM 1.38 billion to Malaysia’s Gross National
Income. This growth has attracted major pharmaceutical and contract research organisations to
expand in Malaysia, increasing the demand for clinical research talent.
In response to this demand, Clinical Research Malaysia (CRM) established the CRM Centre of
Excellence (CoE), officiated by the Minister of Health and Chairman of CRM, YB Datuk Dr Dzulkefly
Ahmad. This program is aimed at developing local talents and providing them a foundation to
kickstart their career in clinical research. The CoE also propels CRM’s Mission 2033 to develop
clinical research professionals in the country by creating 4,000 skilled jobs in clinical research.

10

SPOTLIGHT FEATURE
Malaysia Chosen by International Organisations As Clinical Trial
Hub In The Region

Kuala Lumpur, 9 May 2024 - At the CRM Trial Connect 2024 officiation ceremony, CRM announced a new partnership with Novo
Nordisk (NN) and recognised its ongoing collaboration with AstraZeneca (AZ) in the presence of Minister of Health Datuk Seri Dr Haji
Dzulkefly Ahmad. These partnerships highlight Malaysia's growing role as a global clinical trial hub.
Novo Nordisk, a leading global healthcare company, aims to enhance its strategic trial sites in Malaysia through this collaboration
with CRM. The partnership will boost Malaysia's clinical research landscape. Serdar Kizilcik, Vice-President and General Manager ofNovo Nordisk Malaysia, emphasized the company’s commitment to expanding clinical trials in Malaysia across various therapeuticareas.
Since CRM’s partnership with Sarawak General Hospital (SGH) in early 2023, AstraZeneca has significantly increased its researchpresence in Malaysia, expanding its clinical research workforce by 50% compared to 2022. AstraZeneca has also awarded a First-inHuman (FIH) study to Sarawak General Hospital, led by Dr. Voon Pei Jye, marking Malaysia’s first FIH trial using a biological product.
Additionally, other organisations such as PAREXEL Malaysia and BeiGene, have established their presence in Malaysia, with PAREXEL
setting up a Data Management Centre and BeiGene expanding its R&D and workforce in the country.

Partnership Forged with Singapore Research Organisations

Singapore, 30 July 2024 - The Memorandum of Understanding entered today is aimed to explore potential areas for collaborations inclinical research, that is achieved through understanding of healthcare and research landscape in Singapore and Malaysia.
Through this partnership, all 3 organisations will drive initiatives towards promoting and enabling knowledge exchange, innovationand training to improve the quality of research.
This partnership also enables both SCRI & CADENCE to tap into Malaysia's clinical research networks through CRM's outreach. With
both Malaysia & Singapore leading in clinical research capabilities within Southeast Asia, this collaboration serves as a precursor
towards future joint clinical research initiatives between both nations.

www.clinicalresearch.my

11

RESEARCH PERSONALITYDr Syazatul Syakirin serves as a respiratory consultant at the Institut Perubatan Respiratori(IPR) in Kuala Lumpur. She is a distinguished expert in ILD (Interstitial Lung Disease) and leads
the Malaysia Thoracic Society's (MTS) Special Interest Group in Interstitial Lung Disease (MTSSIG-ILD), fostering knowledge and collaboration in this niche. Her unwavering dedication andpursuit of excellence have established her as a respected figure in respiratory medicine.
She moderates the monthly ILD multidisciplinary conference with the thoracic radiology
group and serves as the Course Advisor and Director for the annual national ILD course.
Additionally, she participates in various MTS initiatives, including spirometry training andthe scientific committee of the annual MTS congress. She spearheads numerous industrysponsored research studies on fibrosing ILD and is globally recognised as a top recruiter in
the Idiopathic Pulmonary Fibrosis study. She also co-authored a chapter on ILD treatment
with renowned expert Prof. Azuma Arata. Her contributions extend internationally throughparticipation in conferences and research endeavours.

12

RESEARCH PERSONALITY

Could you share with us the beginning of your journey as a principal investigator and thechallenges you encountered?
My journey into clinical research began during my second year of respiratory training as a sub-investigator in an asthma study. This
sparked my interest and ambition to lead clinical trials. I diligently gained the necessary skills and began my journey as a principal
investigator with a trial on bronchiectasis. This pivotal moment transitioned my aspirations into reality.
I then had opportunities to research interstitial lung disease (ILD), a field I am passionate about despite its complexity and challenges.
One major challenge was finding patients who met strict study criteria, which required close collaboration with healthcare providers
and thorough screening. Convincing patients to participate was another hurdle, needing clear communication about the study's
purpose, risks, benefits, and their role. Building and maintaining trust through consistent and respectful communication was crucial
to keeping patients engaged and adhering to the protocol. These experiences emphasized the importance of perseverance, strategicplanning, and effective communication in clinical research.
What motivates you to conduct clinical trials?
What motivates me is the opportunity to contribute to cutting-edge therapies that can revolutionize medical practices and benefit
patients worldwide. The prospect of addressing unmet medical needs, enhancing treatment efficacy, and improving patient outcomes
drives my commitment to clinical research.
Tell us an unforgettable accomplishment as an investigator?
An unforgettable accomplish would be the highlight of my achievements in clinical trials includes being the first recruiter in the APAC
region for IPF (ENV-IPF-101) in 2022, and again for the ELEVATE study in 2023. In 2023, I also became the first recruiter in the SEA region
for IPF (1305-0014 FIBRONEER study). Additionally, I was recognised as a top 3 global recruiter and top 2 in the APAC region for the
ELEVATE study.
What is your personal vision as an investigator?
My personal vision is to contribute meaningfully to clinical trials by conducting research that enhances understanding and treatment
options for patients, especially in respiratory diseases. I aim to support advancements in medical knowledge and practice, collaboratingclosely with healthcare professionals to improve patient outcomes and contribute to healthcare innovation.
Could you offer some advice for those who are looking to begin a career in clinical research?
The importance of curiosity, persistence, and a commitment to learning need to be emphasised. It is essential to approach researchwith an open mind and a passion for making a difference in patient care. Stay updated with the current literature and developmentsin own medical field, it will help to develop strong analytical and critical thinking skills.

Standing (L-R): Normaniza Muhammad, Tommy Reysonds bin Thomas, Mardhiyah Abdul Razak,
Nik Nurdiyana Nik Izhar, Sharifah Alia Amilla Syed Hamid, Farhana Hassan & Kamani A/P Vijayan
Seated (L-R): Dr Diyana Sabri, Dr Noraishah Sulaiman, Dr Norni Natriah Mohamad Yusoff, Dr
Syazatul Syakirin Sirol Aflah, Dr Zamzurina Abu Bakar, Dr Normaszuhaila Ab Hamid & Zulsairi
Bin Mohd Pauzi

www.clinicalresearch.my

Dr Syazatul Syakirin at her office13

RISING STARS
IN NEPHROLOGY

About My RoleI started my jou

Since 2012, nephrology studies have surged, with over 80 studies conducted across 60 centres, including health clinics. Majority of
the focus are on chronic kidney diseases, IgA nephropathy, and diabetic kidney disease. Top sites include Hospital Kuala Lumpur,
University Malaya Medical Centre, Raja Permaisuri Bainun Hospital, Tengku Ampuan Afzan Hospital, and Pulau Pinang Hospital. This
growth underscores the dedication and expertise in advancing kidney health and treatment. Dive into the journey of these rising stars
and discover their contributions to advancing kidney health and treatment!

Dr Aida Azlin binti Alias

Dr Fu Mei Sian

Sultan Idris Shah Hospital, Serdang

Sultanah Aminah Hospital,
Johor Bharu

Nephrologist

Areas of Interest in Research

Lupus Nephritis, Focal Segmental Glomerulosclerosis(FSGS), IgA Nephropathy, Membranous Nephropathy,
Diabetic Kidney Disease, Chronic Kidney Disease, End
Stage Kidney Disease and Critical care Nephrology.
I graduated from UKM in 2006, passed the MRCP UK exam in2013, completed a Master’s in Internal Medicine from UKM in
2014, and finished my Nephrology Fellowship with the MOH
Malaysia in 2019. I received a Fellowship from the Royal Collegeof Physicians in 2024.
My research journey began during my master’s programmein 2013. Since then, I have participated in 14 clinical trials asa sub-investigator and have numerous journal publications
and presentations. I was honoured to be selected as Principal
Investigator for a Focal Segmental Glomerulosclerosis (FSGS)
study, successfully randomising the first subject in Malaysia,
which was recognised by CRM.
With the rise of Diabetic Kidney Disease in Malaysia, myresearch focuses on slowing disease progression and reducing
the need for renal replacement therapy. I am also dedicatedto researching other glomerular diseases like Lupus Nephritis,
FSGS, IgA Nephropathy, and Membranous Nephropathy topreserve kidney function and extend kidney survival.

14

Nephrologist

Areas of Interest in Research

Chronic kidney disease, diabetic kidney disease,glomerulonephritis and end stage kidney disease.

I graduated from the Russian State Medical University in 2009 andobtained the MRCP(UK) in October 2016. I completed my Masterof Internal Medicine at University Malaya in May 2018 and a PostGraduate Diabetes Diploma at the University of South Wales, UK,
under a Merck Foundation scholarship in September 2019. By
2023, I had finished my Nephrology sub-specialty training.
In 2017, I received the Merck Diabetes Award for my work onenhancing medication adherence and cardio-metabolic control
in Malaysian type 2 diabetes patients through a smartphone
application. The following year, I won the Best Poster Awardat the Asia Pacific Nephrology Congress and presented at the
Malaysian Congress of Nephrology. My research was publishedin the Journal of Transplantation in 2019. In 2022, I achieved
the Best Poster Award at the World Congress of Nephrology
and presented at both the WCN and the International Society ofNephrology.
I believe advancing research in IgA nephropathy, systemic
lupus nephritis, diabetic kidney disease, and obesity in kidney
patients will need more research in future to delay the diseaseprogression.

RISING STARS IN NEPHROLOGYDr Subasni Govindan
Nephrologist

Tuanku Ja'afar Hospital, Seremban

Areas of Interest in Research

General nephrology, chronic kidney disease andglomerulonephritis

My medical career began in 2008 with an MBBS degree fromAIMST, Kedah. I started as a houseman at Hospital Tuanku
Ampuan Najihah, Kuala Pilah, focusing on Internal Medicine.
This interest led me to pursue a Masters in Internal Medicine
at the University of Malaya. After nearly three years in Kota
Kinabalu as a physician, I specialized in nephrology andcompleted my Malaysian Board of Nephrology Training in 2022.
During my master’s programme, my journey into clinicalresearch began at the University of Malaya. I began conducting
clinical research and have since published and presented at
local and international platforms. I am also actively involved in
TRACK and FIND-CKD clinical trials. My goal as an investigatoris to contribute to advancements in kidney disease treatment
and prevention, improving patient outcomes throughinnovative research.

Dr Mohd Ramadhan Bin
Mohd Din
Nephrologist

Kuala Lumpur Hospital

Areas of Interest in Research

Generalnephrology,
chronic
kidneyhaemodialysis and peritoneal dialysis

disease,I graduated from the National University of Ireland (University
College Dublin) in 2007 and began my medical career with ahousemanship at Hospital Tuanku Ampuan Afzan, Kuantan.
In 2014, I earned my MRCP (UK) from the Royal College ofPhysicians, London, followed by a Masters in Internal Medicine
at the University of Malaya in 2015. After being gazetted asa physician at Hospital Sultan Haji Ahmad Shah Temerloh,
Pahang, I decided to specialize in Nephrology.
In 2019, during my Nephrology training at Hospital Tengku
Ampuan Afzan, I started participating in clinical research as a
sub-investigator for the VALOR-CKD study. I continued this roleat Hospital Tengku Ampuan Rahimah, Klang, in 2020. By 2021,
at the Nephrology Department of Hospital Kuala Lumpur, I
joined several clinical trials, including ACHIEVE, RESOLVE,
CLARION, SIRIUS-LN, and Action3 (Dimerix). Recently, I was
appointed Principal Investigator for the STABILIZE-CKD study
and the upcoming Baxduo Arctic study, set to start in 2024.
As an investigator, I am actively involved in screening andrecruitment patients, support the study team, and provide
expertise to ensure patients receive excellent treatments andbenefit from clinical trials.

My goal as an investigator is to contribute to advancements inkidney diseases treatment and prevention outcomes throughinnovative research
Dr Subasni Govindanwww.clinicalresearch.my15

INFOGRAPHIC
Recruitment Achievements inSponsored Research 2024
Top Global Recruiter
Sultanah Aminah Hospital
Dr Muhhammad Firdaus
Ulcerative Colitis
Tuanku Ja'afar Hospital(Top 4)
Dr Wong Kit Chan
Schizophrenia

Global 1st Recruiter
Sarawak General Hospital
Dr Voon Pei Jye
Non-Small Cell Lung Cancer(NSCLC)
Queen Elizabeth II Hospital
Dr Liew Houng Bang
Acute Myocardial Infection(AMI)

ASIA 1st Recruiter
Sultan Idris Shah Hospital
Dr Fairol Huda Ibrahim
Active Lupus Nephritis

Pulau Pinang Hospital
Dr Choong Swee Hsia
Melanoma

Kuala Lumpur Hospital
Dr Audi Adwiah
Melanoma

Tengku Ampuan
Afzan Hospital
Dr Aishah Ibrahim
Metastatic NSCLC

Malaysia 1st Recruiter
Sultanah Aminah Hospital
Dr Boo Yang Liang
Chronic
Lymphocytic Leukemia
Pantai Hospital
Kuala Lumpur
Dr Mastura Md Yusof• Triple Negative Breast
Cancer• Breast Cancer• Endometrial Cancer• Metastatic Breast Cancer

University Malaya
Medical Center
Assoc. Prof. Dr Wan
Zamaniah
Solid Tumors
Dr Wong Chee Kuan
Chronic Obstructive
Pulmonary Disease
Ampang Hospital
Dr Tan Sen Mui
Follicular Lymphoma andMarginal Zone Lymphoma
Miri Hospital
Dato' Dr Fam Tem Lom• Cardiovascular Disease• Dengue

16

Sultanah Bahiyah Hospital
Dr Zalwani Zainuddin
Functional Dyspepsia
Dr Abd Syukur Abdullah
Heart Failure
Sultanah Fatimah
Specialist Hospital
Dr Evelyn Yap Wen Yee
Chronic Inducible Urticaria
Dr Zaid Bin AzhariUncontrolled Hypertension
Queen Elizabeth II
Hospital
Dr Liew Houng Bang
Atrial Fibrillation
Pulau Pinang Hospital
Dr Soo Hoo Hwoei Fen
Breast Cancer
Tengku Ampuan
Afzan Hospital
Dr Aishah Ibrahim
Chronic Obstructive
Pulmonary Disease
Seri Manjung Hospital
Dr Lee Li Yuan
Gout Patientswith Hyperuricemia

Dr Desmond SamuelResistant Hypertension

Sarawak General Hospital
Dr Chua Hock Hin
HIV-1 Infection

Tuanku Ja’afar Hospital
Dr Toh See Guan
Beta Thalassemia
Major Anemia

Dr Voon Pei Jye
Advanced Solid Tumours(FIH Biologics)

INFOGRAPHIC

www.clinicalresearch.my

17

18

FEATURED SITE
Institut Perubatan Respiratori (IPR)

www.clinicalresearch.my

19

FEATURED SITE.

(L-R) Sharifah Alia Amilla Binti Syed Hamid
and Nik Nurdiyana Binti Nik Izhar.

20

FEATURED SITE

www.clinicalresearch.my

21

MEET OUR TEAM
Alvin Bundoi

Associate Regional Manager
Individual CEO Award 2023 Recipient &Team CEO Award 2020 Recipient.

Alvin has 12 years’ experience in clinical trial industry,currently based in Hospital Queen Elizabeth as
Associate Regional Manager covering East Malaysia A
region.
About My RoleMy roles and responsibilities are to lead, manage, guide,
supervise subordinates and ensure that the clinical trials at sites
are conducted efficiently, effectively and with the utmost quality.
This involves allocating resources, creating plans and budgets,managing staff responsible for the trials at sites, overseeing
trial execution, and managing all sites udner my region.

What inspired you to be part of the clinical researchindustry and what drives you to move forward?

When I was a Study Coordinator, conducting the clinical research
activities according to the protocol, GCP and SOPs was my day
in and out responsibilities, along the years, witnessing patients
battle with chronic illness and observing the impact of clinical
trials on their treatment has opened my eyes to the crucial roleof research in advancing medical knowledge and patient care.

detail. In addition, I had the opportunity to work closely withleading researchers, clinicians, and regulatory experts, whichbroadened my understanding of the clinical trial process.

Important value/criteria that has helps you support
your role.

Integrity is paramount as it ensures all aspects of the process
in any roles, by upholding integrity, it’s not only building trust
and respect but also contributes to a positive work environmentand organizational culture where employees feel valued
and motivated to perform at their best. Embracing integrity
also means being open to feedback, learning from mistakes,
and continuously improving practices to uphold the highest
standards.

In your daily work-life, what keeps you motivated inyour workplace?
It is the combination of purposeful work with the team,collaboration, continuous improvements, and ethicalresponsibility that keeps me motivated and engaged in my daily
work.

This personal connection to the outcomes of clinical trials
inspired me to pursue a career focused on discovering anddeveloping new therapies. The potential to alleviate suffering,
improve quality of life, and cure diseases is incredibly motivating.
Now, with my current role, I aim to inspire and motivate
study coordinators by ensuring a safe working environment,
providing more opportunities, and fostering progressive
improvements so they can become even better than I was before.

What has been your greatest learning opportunity inclinical research?

I like the dynamic nature of clinical research field, with
its constant advancements and challenges, keeps me
engaged and passionate. Being part of CRM team, taught
me invaluable lessons in people and project management,
teamwork, and the importance of meticulous attention to

22

Alvin with his East Malaysia A TeamMEET OUR TEAM

Cheng Shu Hui

Senior Feasibility Specialist

Roles and Responsibilities

I started my clinical research journey with CRM in 2021 asa feasibility specialist, later advancing to senior feasibility
specialist. In this role, I serve as the primary contact for
feasibility enquiries from sponsors, CROs, investigators, andsite personnel. My duties include delegating, managing,coordinating, and overseeing feasibility projects across various
therapeutic areas, ensuring timely responses to clients.
My team and I review scientific literature and clinical practiceguidelines, gathering information on target indications
and investigator feedback to ensure high-quality feasibility
reporting. Each year, our Feasibility Team conducts 'Nurturing
New Talents in Sponsored Research' workshops to foster
interest and understanding of industry-sponsored researchamong investigators and study teams, aiming to promote thegrowth of principal investigators in the country. Additionally,
I am also a member of the Code of Conduct (COC) Committee.

How do feasibility assessments impact clinical trials,
and what are the perspectives from both the site andthe sponsor?

Feasibility assessments are vital in planning and executing
clinical trials. They evaluate whether a trial can be successfully
conducted at a specific site or within a region, ensuring selectedsites are well-equipped for the study. For sites, these assessments
confirm they can meet trial demands according to the study
design and inclusion/exclusion criteria without overextending
resources, including manpower and budget. For sponsors,
they aid in selecting the right sites, managing costs, ensuring
compliance, and maintaining data quality. This collaborative
process enhances the overall efficiency and effectiveness ofclinical trials, leading to more reliable and timely outcomes.

How do you manage feasibility challenges and ensuresmooth trial operations?

Managing feasibility challenges and ensuring smooth trial
operations hinge on strategic planning, detailed analysis,
effective communication, and proactive support. We use theCRMx portal system, which includes all industry-sponsoredresearch at MOH sites and a comprehensive database of potential
investigators from MOH, MOHE, and private sectors. This portal
allows us to thoroughly evaluate trial sites and investigators bywww.clinicalresearch.myassessing their infrastructure, patient population, and past trial
performance. We also analyze historical data to identify trends,
spot potential issues, and optimize site selection.
We maintain regular communication with sites to provide
updates, gather feedback, and address concerns promptly.
Building strong, collaborative relationships with site
investigators, coordinators, and other key stakeholders fosters
a cooperative environment. By leveraging these strategies,
feasibility specialists can enhance site performance, optimize
patient recruitment, ensure regulatory compliance, andmaintain high-quality data, ultimately contributing to thesuccess of clinical trials.

What part of your role do you find most rewarding or
challenging?

As a feasibility specialist, one of the most rewarding aspectsof my role is the sense of accomplishment and teamworkthat comes from meeting tight deadlines or urgent sponsor
requests. Successfully identifying suitable sites, conducting
rapid feasibility assessments under tight timelines, and seeing
the study progress from site selection to activation showcases
our team's expertise and resilience. However, this can also be
one of the most challenging parts, as it requires balancing
thoroughness and speed, managing stress, and ensuring all
stakeholders are aligned and responsive, all while maintaining
the quality and integrity of the feasibility study process.

In your daily work-life, what keeps you motivated inyour workplace?

I stay motivated through a blend of appreciation from sponsors/
CROs, support from colleagues, and personal well-being
practices like brief yoga sessions. Recognition from sponsors
validates our hard work, boosting morale and commitment.
My colleagues' collaborative and positive spirit creates anenergizing work environment, while yoga and mindfulness
exercises help maintain mental clarity and reduce stress. This
combination keeps me motivated and passionate about my role
every day.

23

FEATURED SITE

PUBLICATION

Feasibility Assessments:

What Investigators Need to Know
Journal for Clinical Studies, Volume 16, Issue 1
Authors: Nur Ain Amir, Cheng Shu Hui, Koh Liew Eu & Nur Aziemah Abdul Ghani

The feasibility of clinical trial involves a thorough assessmentof the potential and practicality of conducting a particular trial
within a specified geographic area to ensure a project’s successin terms of timeline, target achievement, cost management, andvarious other essential factors. The extent of feasibility outreachcan constitute an initial assessment phase that provides apreliminary understanding of the disease prevalence andstandard of care. In contrast, an extensive feasibility analysis
encompasses patient criteria, site capabilities, regulatory
requirements, and potential execution challenges, thus
enabling informed decision-making while paving the way for a
successful clinical trial execution and delivery.1 Clinical Research
Malaysia (CRM) provides a centralised feasibility assessment tosponsors and contract research organisations (CROs) to match
clinical trials with the right investigators and sites in Malaysia.
CRM provides reliable insights and up-to- date information thatcovers the hospitals in the public, private, and academia toensure that potential centres and institutions are tapped into
the study.2
This article offers key insights to investigators, underscoring theimportance of feasibility assessments, the impact of feasibility
on successful clinical trials, and recommendations for improving
feasibility responses.

Figure 1: Total full feasibility and pre-feasibility from 2018 - 2023

24

Feasibility Growth and Its ImportanceOver the period spanning from 2018 to 2023, the growth offeasibilities conducted by CRM has been significant (Figure1). In line with this, there has also been an increasing numberof sponsors and Contract Research Organisations (CROs)
conducting feasibility studies through CRM. Based on the annual
customer satisfaction survey reported in the CRM Annual Report
2022, 94% of the respondents rated “good” and “very good” for
CRM’s complimentary feasibility service.
There are a few components that should be considered by clinicalinvestigators when responding to feasibility questionnaires,such as population profile and access,3 facilities and equipment
accessibility, and investigators’ experience.1 Usually, each of
the components has a weight assigned based on the sponsors’
evaluation of the site’s strengths and weaknesses and allows forobjective comparison. Hence, due consideration should be given
to each of the components in completing the questionnaires tomeet the feasibility objective and facilitate site selection.

Estimating Potential Patient
Population
A vital aspect of feasibility assessment is identifying theavailability of patients with a certain disease condition specificto a particular trial. Investigators’ considerations encompass athorough review of the study design, inclusion/exclusion criteria
for patient recruitment, the current standard of care, frequencyof visits, invasiveness level of the trial, and the provision ofreimbursement for study-related procedures.1 Furthermore,correctly identifying the available patient pool, while exercising
caution on underestimation, and ensuring realistic projectionsof patient numbers are crucial aspects to consider.
References from Clinical Practice Guidelines (CPG), up-todate patient registries,4 and the availability of databases suchas the Malaysian Health Data Warehouse (MyHDW) platform,
could provide vital data during feasibility assessments. The
integration of Electronic Medical Records (EMR) within hospitals
supports investigators in providing real-time patient pool for acertain disease condition, further translating to a more reliable
recruitment projection that ultimately meets the recruitment
targets set.

PUBLICATIONSResources and Infrastructure

Assessing infrastructure in healthcare institutions is crucial
in determining the site’s ability to conduct clinical trials.5
A thorough evaluation enables sponsors and investigators
to anticipate and proactively address challenges during thefeasibility stage. Having basic and adequate facilities suchas freezer and fridge for investigational product storage andcentrifuge with regular calibration taking place, will increase thechances of sites being selected during the feasibility assessment.
Considering Malaysia’s resource allocation and population
distribution, certain sites may lack essential diagnostic
capabilities or long waiting times at diagnostic units. The
sites’ readiness to utilize outsourcing services offers a valuable
alternative for obtaining timely results. In addition, it also helps
in mitigating the prolonged turnaround time of test results andalleviates overcrowding issues at public hospital laboratories.
CRM provides the support to connect sponsors and CROs for theoutsourcing services to ensure a successful trial.

Investigators’ Experience andCompeting Studies
Investigators’ experience and their familiarity with the study
protocols are vital for successful studies.6 In addition, identifying
competing studies involving similar patient populations is
crucial for patient recruitment. Investigators are encouraged toshare their trial experience and disclose any ongoing or planned
trials within the same patient pool at a particular locality. This
could prevent challenges in recruiting patients for different trials
which taps into the same patient pool especially if both trials
are taking place at the same time. CRM continuously provides
training to the study teams to uphold the quality of trial conduct
and adherence to the protocol. The trainings include Nurturing
New Talents in Sponsored Research, GCP refresher courses,
Protocol Compliance Workshop, and Patient Recruitment andRetention Workshops.

Challenges and Strategies
One of the challenges in meeting Sponsors’ requirements
includes short timelines given to investigators to complete
feasibility questionnaires, especially if the study is under thebidding stage by a CRO or if it’s a rescue study for an ongoingtrial that is already happening in other parts of the world.
Sponsors may also set short timelines to meet specific businessobjectives and address seasonal considerations, such as disease
outbreaks, which require rapid trial initiation and completion.
With digitalisation playing a larger role in clinical research,sponsors and CROs are introducing new digital platforms to
implement feasibility assessments. Unfamiliarity with the useof these platforms among investigators also poses challenges
in responding to feasibility in a timely manner. To address this,CRM feasibility team and onsite study coordinators support
the investigator in completing the feasibility questionnaire,with input from investigators. Guidelines on navigating thefeasibility platform and support in gathering information fromother departments, such as the laboratory and pharmacy arewww.clinicalresearch.myprovided. This collaborative effort expedites the feasibility
process, leading to quicker site start-up if the sites are selected.
Other strategies aimed at improving feasibility timelines include
the use of e-signatures in Confidential Disclosure Agreements(CDA)8 and utilising online questionnaires/surveys fromsponsors. E-signature is legally recognised under the Electronic
Commerce Act 2006 (ECA) in Malaysia. E-signature offers
flexibility that can aid in recordkeeping, improve efficiency
and deadlines, and reduce the overall timeline for feasibility
assessment. The incorporation of e-signatures and online
surveys aligns with CRM and the industry’s focus on operational
efficiency in clinical trials.

Conclusion
Details and information shared by investigators in feasibility
assessments carry a huge weight in sponsors’ decisions in site
selection. Significant aspects including the availability of thepatient pool, basic facilities, relevant investigator experience,and upcoming competing trials will also ensure that they
can deliver the trial and meet the expectations of sponsors.
Feasibility assessments enable investigators to anticipate
and address challenges in clinical trials, which could facilitate
resource utilisation and the development of effective strategies
in trial initiation. At the end of the day, a good feasibility
assessment and response translates into successful clinical
trials. CRM continuously supports investigators in feasibility
assessments and endeavours to ease communication between
the investigator and sponsor throughout the process.

References
1.

Rajadhyaksha V. Conducting feasibilities in clinical trials: an investment
to ensure a good study. Perspect Clin Res. 2010 Jul;1(3):106-9. PMID:
21814631; PMCID: PMC3146075.

2.

Ooi, A.J.A & Khairul, F.K. A Unique Model to Accelerate IndustrySponsored Research in Malaysia. Journal for Clinical Studies. 11(1),24–27 (2019).

3.

Identifying and selecting a clinical trial for your practice. J Oncol Pract.
2008 Jan;4(1):27-8. doi: 10.1200/JOP.0814602. PMID: 20859441; PMCID:
PMC2793943.

4.

Christian J, Dasgupta N, Jordan M, et al. Digital Health and Patient
Registries: Today, Tomorrow, and the Future. In: Gliklich RE, Dreyer NA,
Leavy MB, et al., editors. 21st Century Patient Registries: Registries for
Evaluating Patient Outcomes: A User’s Guide: 3rd Edition, Addendum[Internet]. Rockville (MD): Agency for Healthcare Research and Quality(US); 2018 Mar. 3. Available from:https://www.ncbi.nlm.nih.gov/books/
NBK493822/

5.

Buse JB, Austin CP, Johnston SC, Lewis-Hall F, March AN, Shore
CK, Tenaerts P, Rutter JL. A framework for assessing clinical trialsite readiness. J Clin Transl Sci. 2023 May 8;7(1):e151. doi: 10.1017/
cts.2023.541. PMID: 37456265; PMCID: PMC10346039.

6.

Cimino J, Braun C. Design a Clinical Research Protocol: Influence of
Real- World Setting. Healthcare (Basel). 2023 Aug 10;11(16):2254. doi:
10.3390/ healthcare11162254. PMID: 37628452; PMCID: PMC10454664.

7.

M.Murad I.M, Johari, N.H, Kuppusamy V., and Yeoh J. CRM Study
Coordinators –Making a Difference in Clinical TrialConduct in Malaysia,
Journal for Clinical Studies Volume 15 Issue 1.

8.

Roslan H.N.S, A. Muis N.S, and A. Rahman N.A Impact of Electronic
Signature Towards Clinical Trial Agreements, Journal for ClinicalStudies, Volume 14 Issue 6

25

CRM IN PHOTOS

CRM with Dr Jane Olivia Lorens, Headof Clinical Research, Siloam Hospital,
Indonesia.

CRM had an engaging meeting with
the Hemophilia Society of Malaysia to
explore potential collaboration on patient
recruitment to raise awareness of clinical
trials among patients.

Geraldine Tong from The Star MediaGroup Berhad's Focus section of the
Sunday edition interviewed CRM
CEO, Dr. Akhmal Yusof at CRM office.

CRM had a catch-up meet with CSI
Medical Research (A ClinChoice
Company).

26

7
May

13
June

27
June

4
July

CRM met with Prof Danny Soon, CEOof the Consortium for Clinical Researchand Innovation Singapore, and the SCRI
team. The introductory meeting aimed tounderstand both organisations.

CRM met IQVIA leaders, including Cynthia
Verst, President of R&D Solutions; Rajneel
Patel, Vice President of Clinical Operations
at DIA2024 Global Annual Meeting in San
Diego.

CRM met with Martin Lim, CEO of
Onward Health Research.

CRM had engaging meet with
SW Strategies team led by Jose
Raymond, the Founder & Managing
Director.

13
May

18
June

3
July

11
July

CRM met with Sansure Biotech, an IVD
diagnostic company from China. Discussion
was on potential diagnostic studies in HPV,
Dengue, and Hepatitis.

CRM met with Celero CEO, Adham Rezk.
Discussion was mainly on sharing CRM's
expertise in conducting clinical research.

CRM met with Dr Yolanda from St
George's University, along with
Shelly and Jean from Wantai
Biopharm.

CRM had touch-base meet with UMMC
team led by Prof Dr Maznah (Head of
Research, Development & Innovation).

21
May

21
June

4
July

11
July

CRM IN PHOTOS

CRM visited Johnson & Johnson’s officeand connected with the Global Clinical
Operations team, including APAC Global
VP Koichi Nishijo and SEA, Australia & New
Zealand Cluster/Country Head Anna Lam.

11
July

Introductory meet with Kent Lee,
Director of Research of Inspire
Medical Systems.

12
July

CRM met with Merck KgaA team.
Discussion was focused on Malaysia'sdelivery on global studies, CRM's initiatives
in upscaling the clinical research talents in
Malaysia and the developments in Merck
Oncology pipeline.

15
July

27

CRM met with Yayasan Jantung Malaysia(YJM) to collaborate on raising clinical trial
awareness among YJM's audience and tounderstand their initiatives and goals for
improving cardiovascular health.

CRM and Novartis teammet to discuss on
Novartis's pipelines, enhancing Malaysia'ssite profile through feasibility and patient
recruitment specialists.

CRM visited the National Kidney
Foundation of Malaysia to explore
collaborative opportunities.

www.clinicalresearch.my

16
July

23
July

25
July

CRM had engaging meet with
Dataxet:Nama team about media
monitoring in enhancing clinicalresearch strategies and outcomes.

CRM touch base meet with KPJ Healthcare
team led by Prof Emeritus Dato' Dr
Lokman, Vice Chancellor of KPJ Healthcare
University College.

CRM met with Oncoshot CEO, Dr Huren
and CCO, Mr Chua Chee Yong to discuss onharnessing the platform for patient cohort
visibility.

16
July

24
July

29
July

CRM connect with Rudi Paye (Strategy& Operations Director) of DNDi, sharing
on CRM's role in sponsored research aswell as on its ongoing initiatives.

CRM and Columbia Asia Bukit Rimau
had an engaging discussion centred on
potential collaboration to utilise CRM’sservices and strategies to attract moreclinical trial opportunities.

CRM met with Isabelle Niekrake and Agnes
Seah from the Embassy of the Kingdomof the Netherlands to discuss CRM’s roleand explore collaboration opportunities
between Malaysia and the Netherlands.

17
July

25
July

31
July
27
27

www.cli ni ca l r esea r ch. my

D-26-06, Menara Suezcap 1, KL Gateway, No. 2 Jalan Kerinchi,
Gerbang Kerinchi Lestari, 59200 Kuala Lumpur, Malaysia.
T: +603-7931 5566 | E: contact@clinicalresearch.my© 2024 Clinical Research Malaysia. All Rights Reserved.

CERTIFIED TO ISO 9001:2015
CERT NO.: QMS 03360

CERTIFIED TO ISO 9001:2015
CERT NO.: QMS 03360